GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (OTCPK:SHJBF) » Definitions » Gross Margin %

Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Gross Margin % : 71.61% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Shanghai Junshi Biosciences Co's Gross Profit for the three months ended in Mar. 2024 was $37.87 Mil. Shanghai Junshi Biosciences Co's Revenue for the three months ended in Mar. 2024 was $52.88 Mil. Therefore, Shanghai Junshi Biosciences Co's Gross Margin % for the quarter that ended in Mar. 2024 was 71.61%.

Warning Sign:

Shanghai Junshi Biosciences Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -6.5%.


The historical rank and industry rank for Shanghai Junshi Biosciences Co's Gross Margin % or its related term are showing as below:

SHJBF' s Gross Margin % Range Over the Past 10 Years
Min: -128.29   Med: 70.09   Max: 88.3
Current: -128.29


During the past 8 years, the highest Gross Margin % of Shanghai Junshi Biosciences Co was 88.30%. The lowest was -128.29%. And the median was 70.09%.

SHJBF's Gross Margin % is ranked worse than
95.86% of 749 companies
in the Biotechnology industry
Industry Median: 60.63 vs SHJBF: -128.29

Shanghai Junshi Biosciences Co had a gross margin of 71.61% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Shanghai Junshi Biosciences Co was -6.50% per year.


Shanghai Junshi Biosciences Co Gross Margin % Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Gross Margin % Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 88.30 76.64 68.74 63.79 55.59

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.48 51.03 - - 71.61

Competitive Comparison of Shanghai Junshi Biosciences Co's Gross Margin %

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Gross Margin % falls into.



Shanghai Junshi Biosciences Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Shanghai Junshi Biosciences Co's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=117 / 210.435
=(Revenue - Cost of Goods Sold) / Revenue
=(210.435 - 93.455) / 210.435
=55.59 %

Shanghai Junshi Biosciences Co's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=37.9 / 52.878
=(Revenue - Cost of Goods Sold) / Revenue
=(52.878 - 15.01) / 52.878
=71.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Shanghai Junshi Biosciences Co  (OTCPK:SHJBF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Shanghai Junshi Biosciences Co had a gross margin of 71.61% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Shanghai Junshi Biosciences Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (Shanghai Junshi Biosciences Co) Headlines